The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

Robert BissonnetteC MaariS FormanN BhatiaM LeeJ FowlerS TyringD PariserH SofenS DhawanM ZookD J ZammitH UsanskyL DenisN RaoT SongA B PavelEmma Guttman-Yassky

Published in: The British journal of dermatology (2019)

In patients with moderate-to-severe AD, ASN002 showed strong efficacy with rapid onset of action and associated improvements in systemic inflammation.

Keyphrases

double blind
atopic dermatitis
early onset
high intensity
clinical trial
placebo controlled
study protocol
tyrosine kinase
drug induced
protein kinase
open label
quantum dots